Gendered neuroplasticity in psychedelic microdosing reveals systemic biases in biomedical research paradigms
Original framing: “Microdosing LSD shows some cognitive benefits — but only for women” — Nature
Women of color, neurodivergent individuals, and those with disabilities are systematically excluded from psychedelic research, yet their experiences may reveal critical insights. For example, Black women in the U.S. have historically used psychedelics in spiritual practices (e.g., *rootwork* traditions) despite medical marginalization. The study’s sample likely overrepresents white, able-bodied, cisgender participants, obscuring how intersectional identities shape psychedelic effects. Marginalized voices also highlight the ethical risks of psychedelic tourism, where Westerners exploit Indigenous lands for 'transformative' experiences while local communities face criminalization.
The Nature study’s gendered LSD findings are not an isolated biological quirk but a symptom of deeper systemic failures: the erasure of Indigenous knowledge, the historical exclusion of women from biomedical research, and the neoliberal capture of psychedelics by venture capital.
What appears as a 'new' scientific discovery is often a belated correction of past harms, while the framing obscures how gendered drug responses are shaped by cultural, socioeconomic, and historical factors. The trickster lens reveals the absurdity of Western science 'rediscovering' what Indigenous women have known for millennia, while the marginalized voices dimension exposes how current research designs perpetuate exclusion. To move forward, solutions must center Indigenous governance, intersectional research, and ethical frameworks that prioritize cultural integrity over commercial extraction—otherwise, we risk repeating the cycles of exploitation that define modern psychiatry.